We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+33.72%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$783M
AUM Growth
+$288M
Cap. Flow
+$190M
Cap. Flow %
24.26%
Top 10 Hldgs %
60.08%
Holding
55
New
12
Increased
17
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$54M
2
ARRY
Array Biopharma Inc
ARRY
+$38.5M
3
TSRO
TESARO, Inc.
TSRO
+$29.3M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$21.5M
5
PCRX icon
Pacira BioSciences
PCRX
+$17.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$20.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$16.7M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 75.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$67.9M 8.67%
10,488,076
+1,224,736
+13% +$6.2M
TSRO
2
DELISTED
TESARO, Inc.
TSRO
$63.4M 8.09%
411,823
+180,123
+78% +$29.3M
MDCO
3
DELISTED
Medicines Co
MDCO
$57.9M 7.4%
+1,185,000
New +$54M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.51B
$56M 7.16%
1,630,000
+143,540
+10% +$5.07M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$51.8M 6.62%
590,000
+190,000
+48% +$16.9M
DERM
6
DELISTED
Dermira, Inc.
DERM
$41M 5.24%
1,202,313
+436,604
+57% +$14.1M
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$34.6M 4.42%
4,847,577
+830,000
+21% +$5.25M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.04B
$33.9M 4.33%
4,551,343
+30,700
+0.7% +$225K
ARRY
9
DELISTED
Array Biopharma Inc
ARRY
$33.8M 4.32%
3,780,000
+3,620,000
+2,263% +$38.5M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$30M 3.84%
815,000
-180,838
-18% -$4.55M
TLGT
11
DELISTED
Teligent, Inc
TLGT
$29.6M 3.78%
379,151
+212,789
+128% +$15.3M
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$28.3M 3.61%
450,000
+154,467
+52% +$9.64M
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
$22.5M 2.88%
+353,900
New +$21.5M
ASND icon
14
Ascendis Pharma A/S
ASND
$16.5B
$19.6M 2.51%
700,924
+155,721
+29% +$3.94M
AERI
15
DELISTED
Aerie Pharmaceuticals
AERI
$19.3M 2.46%
425,000
-185,000
-30% -$8.25M
PCRX icon
16
Pacira BioSciences
PCRX
$1.04B
$18.7M 2.39%
+410,000
New +$17.7M
ASMB icon
17
Assembly Biosciences
ASMB
$498M
$17.8M 2.27%
58,034
+35,510
+158% +$8.71M
AVXS
18
DELISTED
AveXis, Inc. Common Stock
AVXS
$17.1M 2.19%
+225,370
New +$13.9M
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$15.7M 2%
590,000
-466,303
-44% -$11.6M
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.42B
$13.5M 1.72%
1,603,001
-28,501
-2% -$198K
AGEN
21
Agenus
AGEN
$276M
$12.7M 1.62%
171,642
-19,442
-10% -$1.54M
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.4M 1.58%
2,383,201
+875,000
+58% +$4.8M
VNDA icon
23
Vanda Pharmaceuticals
VNDA
$304M
$8.64M 1.1%
617,200
+235,734
+62% +$3.36M
VCYT icon
24
Veracyte
VCYT
$4.45B
$8.33M 1.06%
906,999
– –
ALIM
25
DELISTED
Alimera Sciences
ALIM
$8.11M 1.04%
386,105
+117,139
+44% +$2.26M
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Avoro Capital Advisors held 55 positions worth $783M, up 58% from $495M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors deployed $190M of net new capital in Q1 2017, opening 12 new positions and adding to 17 existing holdings. Its largest new stake was Medicines Co: 1,185,000 shares worth $57.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier.

On the sell side, the largest reduction was NeuroDerm Ltd. Ordinary Shares, an estimated $11.6M trimmed.

  • Avoro Capital Advisors's largest Q1 2017 buy was Medicines Co: 1,185,000 shares worth $57.9M.
  • Avoro Capital Advisors added most to Array Biopharma Inc in Q1 2017, an estimated $38.5M increase.
  • Avoro Capital Advisors's biggest Q1 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $11.6M.
  • Avoro Capital Advisors fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $27.7M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $783M portfolio in Q1 2017.
  • Avoro Capital Advisors opened 12 new positions and closed 10 in Q1 2017.
  • Avoro Capital Advisors's portfolio value rose 58% quarter-over-quarter to $783M.

Based on Avoro Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.